Salarius Pharmaceuticals, Inc. (SLRX) DCF Valuation

Salarius Pharmaceuticals, Inc. (SLRX) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Salarius Pharmaceuticals, Inc. (SLRX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain insight into your Salarius Pharmaceuticals, Inc. (SLRX) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real (SLRX) data, enabling you to adjust forecasts and assumptions for an accurate calculation of Salarius Pharmaceuticals' intrinsic value.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 3.5 5.2 1.8 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 51.03 -64.84 -100 0 -28.45 -28.45 -28.45 -28.45 -28.45
EBITDA -6.9 -7.3 -12.7 -31.6 .0 .0 .0 .0 .0 .0
EBITDA, % -199.74 -140.09 -692.8 100 100 -20 -20 -20 -20 -20
Depreciation .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Depreciation, % 0.48871 0.34506 1.04 100 100 40.38 40.38 40.38 40.38 40.38
EBIT -6.9 -7.3 -12.8 -31.6 .0 .0 .0 .0 .0 .0
EBIT, % -200.23 -140.43 -693.84 100 100 -20 -20 -20 -20 -20
Total Cash 3.7 11.1 29.2 12.1 5.9 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 3.9 .0 1.6 .0
Account Receivables, % 0 73.68 0 100 100
Inventories .0 .0 .0 -1.6 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 0 100 100 40 40 40 40 40
Accounts Payable 1.8 1.9 1.5 2.9 .6 .0 .0 .0 .0 .0
Accounts Payable, % 51.69 35.42 83.85 100 100 74.19 74.19 74.19 74.19 74.19
Capital Expenditure .0 .0 .0 -1.5 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 0 -0.04968184 0 100 100 -0.00993637 -0.00993637 -0.00993637 -0.00993637 -0.00993637
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -5.6 -7.1 -12.7 -31.4 .0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -3.8 -10.9 -9.1 -31.6 -2.3 -.6 .0 .0 .0 .0
WACC, % 8.58 8.62 8.63 8.63 8.63 8.62 8.62 8.62 8.62 8.62
PV UFCF
SUM PV UFCF -.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -6
Equity Value 5
Diluted Shares Outstanding, MM 3
Equity Value Per Share 1.55

What You Will Get

  • Real Salarius Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Salarius Pharmaceuticals, Inc. (SLRX).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Salarius Pharmaceuticals, Inc. (SLRX).
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Salarius Pharmaceuticals, Inc. (SLRX)’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections relevant to Salarius Pharmaceuticals, Inc. (SLRX).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Salarius Pharmaceuticals, Inc. (SLRX).

Key Features

  • Comprehensive Data: Salarius Pharmaceuticals' historical financial statements and pre-filled forecasts.
  • Customizable Variables: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: Monitor Salarius Pharmaceuticals' intrinsic value as it updates live.
  • Intuitive Visualizations: Interactive dashboard charts present valuation outcomes and essential metrics.
  • Engineered for Precision: A reliable tool tailored for analysts, investors, and finance professionals.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Salarius Pharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Salarius Pharmaceuticals’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Salarius Pharmaceuticals, Inc. (SLRX)?

  • Accurate Data: Up-to-date Salarius financials provide dependable valuation outcomes.
  • Customizable: Modify essential factors such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Built-in calculations save you from starting from the ground up.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
  • User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.

Who Should Use Salarius Pharmaceuticals, Inc. (SLRX)?

  • Investors: Gain insights into innovative cancer therapies and make informed investment choices.
  • Healthcare Analysts: Utilize comprehensive data to evaluate market potential and company performance.
  • Biotech Consultants: Tailor presentations and reports with up-to-date information on Salarius’ pipeline.
  • Pharmaceutical Enthusiasts: Explore cutting-edge research and development in oncology to enhance your knowledge.
  • Educators and Students: Incorporate real-world case studies into your curriculum on biotechnology and pharmaceuticals.

What the Template Contains

  • Pre-Filled Data: Includes Salarius Pharmaceuticals' historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Salarius Pharmaceuticals' profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.